HC Wainwright Issues Pessimistic Estimate for QUIT Earnings

Achieve Life Sciences, Inc. (NASDAQ:QUIT) – Analysts at HC Wainwright dropped their FY2029 earnings per share estimates for Achieve Life Sciences in a research note issued to investors on Wednesday, November 11th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of $0.92 per share for the year, down from their previous estimate of $0.97. HC Wainwright also issued estimates for Achieve Life Sciences’ FY2030 earnings at $1.39 EPS.

Several other brokerages have also recently weighed in on QUIT. Zacks Research started coverage on shares of Achieve Life Sciences in a research report on Tuesday. They set a “hold” rating for the company. Weiss Ratings assumed coverage on shares of Achieve Life Sciences in a research report on Wednesday. They issued a “sell (d-)” rating on the stock. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Reduce”.

Achieve Life Sciences Price Performance

About Achieve Life Sciences

Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for nicotine dependence. Its lead product candidate, cytisinicline, is being studied as a potential aid for people seeking to stop smoking or using other nicotine products. Cytisinicline is a plant-derived compound that acts on nicotine receptors in the brain. The company is conducting clinical development with the goal of obtaining regulatory approval; the candidate is not an approved treatment.